← All trials
NCT06314867
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2023
- Primary completion
- Dec 30, 2024
- Completion date
- Jun 30, 2028
- First posted
- Mar 18, 2024
- Last posted
- Apr 4, 2024
- Enrollment
- 990
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.